<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069558</url>
  </required_header>
  <id_info>
    <org_study_id>OCC2021_02</org_study_id>
    <nct_id>NCT05069558</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Multi-center Controlled Clinical Investigation Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion.</brief_title>
  <official_title>Prospective Randomized Multi-center Controlled Clinical Investigation Comparing Patent Foramen Ovale (PFO) Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Occlutech International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Occlutech International AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate whether percutaneous PFO closure with the&#xD;
      Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore®&#xD;
      Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and&#xD;
      device/procedure related Serious Adverse Events (SAE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 26, 2021</start_date>
  <completion_date type="Anticipated">October 26, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 26, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective Closure Rate of PFO</measure>
    <time_frame>Twelve Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-Fatal Recurrent Stroke</measure>
    <time_frame>Enrollment to 12 Months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety: Device and Procedure Related Serious Adverse Events</measure>
    <time_frame>Enrollment to Twelve Months, Annually thereafter.</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Stroke</condition>
  <condition>Patent Foramen Ovale</condition>
  <arm_group>
    <arm_group_label>Investigational PFO Closure Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PFO closure with the study Occlutech Flex II PFO device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care PFO Closure Device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PFO closure with either of the standard of care PFO occlusion devices; Amplatzer PFO Occluder or the Gore Cardioform PFO Occluder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Investigational PFO Closure Device</intervention_name>
    <description>Occlutech Flex II PFO Closure Device</description>
    <arm_group_label>Investigational PFO Closure Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard of Care PFO Closure Device</intervention_name>
    <description>Amplatzer PFO Occluder and Gore Cardioform PFO Occluder</description>
    <arm_group_label>Standard of Care PFO Closure Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects with a PFO and cryptogenic stroke:&#xD;
&#xD;
        PFO defined as visualization of microbubbles (during Trans Esophageal Echo (TEE)) in the&#xD;
        left atrium within three cardiac cycles of right atrial opacification at rest and/or with&#xD;
        Valsalva.&#xD;
&#xD;
        Cryptogenic stroke defined as a stroke of unknown cause.&#xD;
&#xD;
        Stroke defined as an acute focal neurological deficit, presumed to be due to focal&#xD;
        ischemia, and either:&#xD;
&#xD;
        Symptoms persisting ≥24 hours, or&#xD;
&#xD;
        Symptoms persisting &lt;24 hours with Magnetic Resonance Imaging (MRI) or Computer Tomography&#xD;
        (CT) findings of a new, neuroanatomically relevant, cerebral infarct.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria: Age &lt;18 years&#xD;
&#xD;
        Myocardial Infarction (MI) or unstable angina within 6 months&#xD;
&#xD;
        Mitral or aortic valve stenosis or severe regurgitation&#xD;
&#xD;
        Left Ventricle Ejection Fraction (LVEF) &lt;35%&#xD;
&#xD;
        Uncontrolled hypertension or diabetes mellitus despite medications&#xD;
&#xD;
        Subjects contraindicated for aspirin or clopidogrel&#xD;
&#xD;
        Subjects not able to discontinue anticoagulation&#xD;
&#xD;
        Qualifying stroke with Modified Rankin score &gt;3&#xD;
&#xD;
        Anatomy in which the device would interfere with intracardiac or vascular structures&#xD;
&#xD;
        Life expectancy &lt; 2 years&#xD;
&#xD;
        Exclusion for patients with known causes of ischemic stroke:&#xD;
&#xD;
        Atrial fibrillation/atrial flutter (chronic or intermittent)&#xD;
&#xD;
        Left Ventricle (LV) aneurysm, intracardiac thrombus, or tumor&#xD;
&#xD;
        Mitral or aortic valve vegetation or prosthesis&#xD;
&#xD;
        Aortic arch plaques protruding &gt;4 mm into the lumen&#xD;
&#xD;
        Atherosclerosis or arteriopathy of intra- or extracranial vessels with &gt;50% diameter&#xD;
        stenosis in the artery supplying the infarcted territory&#xD;
&#xD;
        Another cause of right-to-left shunting (e.g., an Atrial Septal Defect (ASD) or a&#xD;
        fenestrated atrial septum)&#xD;
&#xD;
        Presence of an arterial hypercoagulable state:&#xD;
&#xD;
        Lupus anticoagulant,&#xD;
&#xD;
        anticardiolipin Abs,&#xD;
&#xD;
        hyperhomocysteinemia,&#xD;
&#xD;
        Cancer-related hypercoagulability.&#xD;
&#xD;
        Lacunar infarct probably due to intrinsic small vessel as the qualifying event, defined as&#xD;
        an ischemic stroke in the distribution of a single, small deep penetrating vessel in a&#xD;
        patient with any of the following:&#xD;
&#xD;
        A history of hypertension (except in the first week post stroke)&#xD;
&#xD;
        A history of diabetes mellitus&#xD;
&#xD;
        Age ≥50 years&#xD;
&#xD;
        MRI or CT with leukoaraiosis greater than symmetric, well-defined periventricular caps, or&#xD;
        bands (European Task Force on Age-Related White Matter Changes rating scale score &gt;0)&#xD;
&#xD;
        Arterial dissection as the qualifying event&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susan G. Wiskow</last_name>
    <phone>6122839263</phone>
    <email>susan.wiskow@occlutech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ken Lock</last_name>
    <email>kenneth.lock@occlutech.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

